Advanced

A Critical Evaluation of Inflammatory Markers in Huntington’s Disease Plasma

Silajdzic, Edina LU ; Rezeli, Melinda LU ; Végvári, Ákos LU ; Lahiri, Nayana; Andre, Ralph; Magnusson-Lind, Anna LU ; Nambron, Rajasree; Kalliolia, Eirini; Marko-Varga, György LU and Warner, Thomas T., et al. (2013) In Journal of Huntington's Disease 2(1). p.125-134
Abstract
BACKGROUND: Huntington’s Disease (HD) is a hereditary, progressive neurodegenerative disorder characterised by both neurological and systemic symptoms. In HD, immune changes can be observed before the onset of overt clinical features raising the possibility that immune markers in plasma could be used to track disease progression. It has previously been demonstrated that a widespread, progressive innate immune response is detectable in plasma throughout the course of HD.

OBJECTIVE: The aim of the present study was to investigate the potential of several components of innate immunity as plasma biomarkers in HD.

METHODS: We utilised antibody-based detection technologies as well as mass spectrometric quantification,... (More)
BACKGROUND: Huntington’s Disease (HD) is a hereditary, progressive neurodegenerative disorder characterised by both neurological and systemic symptoms. In HD, immune changes can be observed before the onset of overt clinical features raising the possibility that immune markers in plasma could be used to track disease progression. It has previously been demonstrated that a widespread, progressive innate immune response is detectable in plasma throughout the course of HD.

OBJECTIVE: The aim of the present study was to investigate the potential of several components of innate immunity as plasma biomarkers in HD.

METHODS: We utilised antibody-based detection technologies as well as mass spectrometric quantification, multiple reaction monitoring (MRM-MS).

RESULTS: Levels of several markers previously described as altered in HD, such as clusterin, complement component 4, complement component 9 and α-2 macroglobulin did not differ between healthy controls and HD subjects as measured by Luminex, ELISA or MRM-MS. C-reactive protein was decreased in early HD, while the other immune markers tested were unaltered.

CONCLUSIONS: Of the immune markers tested in this study, none showed potential to track with HD disease progression. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Huntington's Disease
volume
2
issue
1
pages
125 - 134
publisher
IOS Press
external identifiers
  • Scopus:84902531241
ISSN
1879-6397
DOI
10.3233/JHD-130049
language
English
LU publication?
yes
id
79510f4d-e755-466b-b153-a4dec613c9c8 (old id 3460893)
date added to LUP
2013-04-02 14:47:55
date last changed
2016-10-13 04:34:40
@misc{79510f4d-e755-466b-b153-a4dec613c9c8,
  abstract     = {BACKGROUND: Huntington’s Disease (HD) is a hereditary, progressive neurodegenerative disorder characterised by both neurological and systemic symptoms. In HD, immune changes can be observed before the onset of overt clinical features raising the possibility that immune markers in plasma could be used to track disease progression. It has previously been demonstrated that a widespread, progressive innate immune response is detectable in plasma throughout the course of HD. <br/><br>
OBJECTIVE: The aim of the present study was to investigate the potential of several components of innate immunity as plasma biomarkers in HD. <br/><br>
METHODS: We utilised antibody-based detection technologies as well as mass spectrometric quantification, multiple reaction monitoring (MRM-MS). <br/><br>
RESULTS: Levels of several markers previously described as altered in HD, such as clusterin, complement component 4, complement component 9 and α-2 macroglobulin did not differ between healthy controls and HD subjects as measured by Luminex, ELISA or MRM-MS. C-reactive protein was decreased in early HD, while the other immune markers tested were unaltered. <br/><br>
CONCLUSIONS: Of the immune markers tested in this study, none showed potential to track with HD disease progression.},
  author       = {Silajdzic, Edina and Rezeli, Melinda and Végvári, Ákos and Lahiri, Nayana and Andre, Ralph and Magnusson-Lind, Anna and Nambron, Rajasree and Kalliolia, Eirini and Marko-Varga, György and Warner, Thomas T. and Laurell, Thomas and Tabrizi, Sarah J. and Björkqvist, Maria},
  issn         = {1879-6397},
  language     = {eng},
  number       = {1},
  pages        = {125--134},
  publisher    = {ARRAY(0x8efd758)},
  series       = {Journal of Huntington's Disease},
  title        = {A Critical Evaluation of Inflammatory Markers in Huntington’s Disease Plasma},
  url          = {http://dx.doi.org/10.3233/JHD-130049},
  volume       = {2},
  year         = {2013},
}